BACKGROUND: Both angina and dyspnea are prevalent symptoms among post-myocardial infarction (MI) patients. Given their frequent overlap, little is known about the degree to which these symptoms provide independent information in this population. METHODS: Using the multicenter Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER), 1,835 patients were administered the Rose Dyspnea Scale (scores range 0-4; higher scores indicate worse dyspnea), Seattle Angina Questionnaire (SAQ; lower scores indicate worse angina), and 12-item Short Form physical component (PCS; lower scores indicate worse physical health status) at 1 and 12 months post-MI. Multivariable regression was used to examine the association between dyspnea and quality of life (QOL) in both cross-sectional and longitudinal analyses as well as its association with rehospitalizations and mortality. RESULTS: At 1-month follow-up, 863 patients (47%) reported dyspnea, and 340 (19%) noted moderate to severe dyspnea. After adjusting for sociodemographic and clinical factors including SAQ angina frequency, higher dyspnea scores remained strongly associated with worse QOL in both cross-sectional (1-U dyspnea increase = 2.5-point PCS decrease and 2.4-point SAQ QOL decrease) and longitudinal analyses (1-U dyspnea increase from 1 month to 1 year = 3.8-point PCS decrease and 3.5-point SAQ QOL decrease), and with increased risk of 1-year rehospitalization (hazard ratio 1.15/1 U of dyspnea, 95% CI 1.07-1.24) and 3-year mortality (hazard ratio 1.34/1 U of dyspnea, 95% CI 1.19-1.51; P < .001 for all analyses). CONCLUSIONS: Among post-MI patients, dyspnea is common and strongly associated with impaired QOL, more frequent rehospitalization, and reduced survival--independent of both clinical factors and angina. These findings suggest that dyspnea is an important component of disease-specific health status for post-MI patients, and its assessment should be strongly considered in both research studies and clinical practice.
BACKGROUND: Both angina and dyspnea are prevalent symptoms among post-myocardial infarction (MI) patients. Given their frequent overlap, little is known about the degree to which these symptoms provide independent information in this population. METHODS: Using the multicenter Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER), 1,835 patients were administered the Rose Dyspnea Scale (scores range 0-4; higher scores indicate worse dyspnea), Seattle Angina Questionnaire (SAQ; lower scores indicate worse angina), and 12-item Short Form physical component (PCS; lower scores indicate worse physical health status) at 1 and 12 months post-MI. Multivariable regression was used to examine the association between dyspnea and quality of life (QOL) in both cross-sectional and longitudinal analyses as well as its association with rehospitalizations and mortality. RESULTS: At 1-month follow-up, 863 patients (47%) reported dyspnea, and 340 (19%) noted moderate to severe dyspnea. After adjusting for sociodemographic and clinical factors including SAQ angina frequency, higher dyspnea scores remained strongly associated with worse QOL in both cross-sectional (1-U dyspnea increase = 2.5-point PCS decrease and 2.4-point SAQ QOL decrease) and longitudinal analyses (1-U dyspnea increase from 1 month to 1 year = 3.8-point PCS decrease and 3.5-point SAQ QOL decrease), and with increased risk of 1-year rehospitalization (hazard ratio 1.15/1 U of dyspnea, 95% CI 1.07-1.24) and 3-year mortality (hazard ratio 1.34/1 U of dyspnea, 95% CI 1.19-1.51; P < .001 for all analyses). CONCLUSIONS: Among post-MI patients, dyspnea is common and strongly associated with impaired QOL, more frequent rehospitalization, and reduced survival--independent of both clinical factors and angina. These findings suggest that dyspnea is an important component of disease-specific health status for post-MI patients, and its assessment should be strongly considered in both research studies and clinical practice.
Authors: Mouin S Abdallah; Kaijun Wang; Elizabeth A Magnuson; John A Spertus; Michael E Farkouh; Valentin Fuster; David J Cohen Journal: JAMA Date: 2013-10-16 Impact factor: 56.272
Authors: Jesse Xiaolong Yang; Margaret J Stevenson; Linda Valsdottir; Kalon Ho; John A Spertus; Robert W Yeh; Jordan B Strom Journal: Heart Date: 2019-12-19 Impact factor: 5.994
Authors: Mohammed Qintar; Taishi Hirai; Suzanne V Arnold; Justin Sheehy; James Sapontis; Phil Jones; Yuanyuan Tang; William Lombardi; Dimitri Karmpaliotis; Jeffery Moses; Christian Patterson; William J Nicholson; David J Cohen; John A Spertus; J Aaron Grantham; Adam C Salisbury Journal: Am Heart J Date: 2019-04-26 Impact factor: 4.749
Authors: Panaiotis Finamore; Martijn A Spruit; Jos M G A Schols; Raffaele Antonelli Incalzi; Emiel F M Wouters; Daisy J A Janssen Journal: Aging Clin Exp Res Date: 2020-04-11 Impact factor: 3.636
Authors: Mohammed Qintar; J Aaron Grantham; James Sapontis; Kensey L Gosch; William Lombardi; Dimitri Karmpaliotis; Jeffery Moses; Adam C Salisbury; David J Cohen; John A Spertus; Suzanne V Arnold Journal: Circ Cardiovasc Qual Outcomes Date: 2017-12
Authors: Laura P Kimble; Sandra B Dunbar; William S Weintraub; Deborah B McGuire; Sharon F Manzo; Ora L Strickland Journal: J Adv Nurs Date: 2011-02-24 Impact factor: 3.187
Authors: Michael C Kontos; David E Lanfear; Kensey Gosch; Stacie L Daugherty; Paul Heidenriech; John A Spertus Journal: Am J Cardiol Date: 2017-04-27 Impact factor: 2.778
Authors: Krishna K Patel; Firas Al Badarin; Paul S Chan; John A Spertus; Staci Courter; Kevin F Kennedy; James A Case; A Iain McGhie; Gary V Heller; Timothy M Bateman Journal: JACC Cardiovasc Imaging Date: 2019-07-17
Authors: Adaire E Prosser; Jessica L Dawson; KethLyn Koo; Karen M O'Kane; Michael B Ward; Richard J Woodman; Arduino A Mangoni; Cameron J Phillips Journal: Ther Adv Drug Saf Date: 2018-08-09